Susceptibility and bactericidal activity of 8 oral quinolones against conventional-fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates

Diagnostic Microbiology and Infectious Disease

Volumn 65, Issue 1, 2009, Pages 76-80

  Yokota, Shin ichi ^a   Ohkoshi, Yasuo ^a   Fujii, Nobuhiro ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antibiotic resistance; PK PD; Quinolones; Respiratory tract infection; Streptococcus pneumoniae

Indexed keywords

6 FLUORO 1 METHYL 4 OXO 7 (1 PIPERAZINYL) 4H 1,3 THIAZETO[3,2 A]QUINOLINE 3 CARBOXYLIC ACID; CIPROFLOXACIN; GARENOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PRULIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; SPARFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; ERADICATION THERAPY; JAPAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; JAPAN; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PNEUMOCOCCAL INFECTIONS; QUINOLONES; STREPTOCOCCUS PNEUMONIAE;

EID: 68249109849     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.05.006     Document Type: Article

References (16)

1. Ambrose P.G., Grasela D.M., Grasela T.H., Passarell J., Mayer H.B., and Pierce P.F. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45 (2001) 2793-2797
2. Blondeau J.M., Zhao X., Hansen G., and Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45 (2001) 433-438
3. Canton R., Morosini M., Enright M.C., and Morrissey I. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J. Antimicrob. Chemother. 52 (2003) 944-952
4. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, M07-A7. seventh edition (2006), CLSI, Wayne, PA
5. Fung-Tomc J.C., Minassian B., Kolek B., Huczko E., Aleksunes L., Stickle T., Washo T., Gradelski E., Valera L., and Bonner D.P. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob. Agents Chemother. 44 (2000) 3351-3356
6. Grohs P., Houssaye S., Aubert A., Gutmann L., and Varon E. In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones. Antimicrob. Agents Chemother. 47 (2003) 3542-3547
7. Jones R.N., Fritsche T.R., Sader H.S., and Stilwell M.G. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values. Diagn. Microbiol. Infect. Dis. 58 (2007) 9-17
8. Lister P.D. Impact of AUC/MIC ratios on the pharmacodynamics of the des-F(6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones. J. Antimicrob. Chemother. 51 (2003) 199-202
9. Madaras-Kelly K.J., and Demasters T.A. In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 37 (2000) 253-260
10. Morosini M.I., Loza E., del Campo R., Almaraz F., Baquero F., and Canton R. Fluoroquinolone-resistant Streptococcus pneumoniae in Spain: activities of garenoxacin against clinical isolates including strains with altered topoisomerases. Antimicrob. Agents Chemother. 47 (2003) 2692-2695
11. Takahata M., Mitsuyama J., Yamashiro Y., Yonezawa M., Araki H., Todo Y., Minami S., Watanabe Y., and Narita H. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob. Agents Chemother. 43 (1999) 1077-1084
12. Ubukata K. Problems associated with high prevalence of multidrug-resistant bacteria in patients with community-acquired infections. J. Infect. Chemother. 9 (2003) 285-291
13. Weller T.M., Andrews J.M., Jevons G., and Wise R. The in vitro activity of BMS-284756, a new des-fluorinated quinolone. J. Antimicrob. Chemother. 49 (2002) 177-184
14. Wright D.H., Brown G.H., Peterson M.L., and Rotschafer J.C. Application of fluoroquinolone pharmacodynamics. J. Antimicrob. Chemother. 46 (2000) 669-683
15. Yokota S., Sato K., Kuwahara O., Habadera S., Tsukamoto N., Ohuchi H., Akizawa H., Himi T., and Fujii N. Fluoroquinolone-resistant Streptococcus pneumoniae strains occur frequently in elderly patients in Japan. Antimicrob. Agents Chemother. 46 (2002) 3311-3315
16. Yokota S., Sato K., Yoshida S., and Fujii N. Molecular epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae in Japan. (in Japanese). Kansenshogaku Zasshi 78 (2004) 428-434